• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by SPK Acquisition Corp.

    5/17/22 11:06:14 AM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials
    Get the next $SPK alert in real time by email
    NT 10-Q 1 spk_nt10q.htm

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 12b-25

     

      NOTIFICATION OF LATE FILING SEC FILE NUMBER
    001 40462 
        CUSIP NUMBER
    848651105

     

    (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR

     

    For Period Ended: March 31, 2022

     

    ☐ Transition Report on Form 10-K
    ☐ Transition Report on Form 20-F
    ☐ Transition Report on Form 11-K
    ☐ Transition Report on Form 10-Q
    ☐ Transition Report on Form N-SAR

    For the Transition Period Ended: _______________

     

    Read attached instruction sheet before preparing form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
     

     

    PART I

    REGISTRANT INFORMATION

     

    Full Name of Registrant
     
    SPK Acquisition Corp.
    Former Name if Applicable
     
    Address of Principal Executive Office (Street and Number)
    Room 368, 302 Buwei
    211 Fute North Road
     
    City, State and Zip Code
     
    China (Shanghai) Pilot Free Trade Zone, 200131

     

     

     

     

    PART II
    RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a)  The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR or From N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III
    NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    The Quarterly Report on Form 10-Q of SPK Acquisition Corp. (the “Company”) could not be filed within the prescribed time period due to the fact that the Company was unable to finalize its financial results without unreasonable expense or effort. As a result, the Company could not solicit and obtain the necessary review of the Form 10-Q in a timely fashion prior to the due date of the report.

     

    PART IV
    OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification  

     

      Sophie Ye Tao   +86   34-3912-9879
      (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter) period that the registrant was required to file such reports) been filed? If answer is no, identify report(s).   ☒ Yes ☐ No
           
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?   ☐ Yes ☒ No
           
      If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.    

     

     

     

     

    SPK Acquisition Corp.
    (Name of Registrant as Specified in Charter)

     

    Has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 17, 2022 By: /s/ Sophie Ye Tao
        Name:  Sophie Ye Tao
        Title: Chief Executive Officer

     

    INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

    GENERAL INSTRUCTIONS

     

    1. This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under the Securities Exchange Act of 1934.

     

    2. One signed original and four conformed copies of this form and amendments thereto must be completed and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations under the Act. The information contained in or filed with the form will be made a matter of public record in the Commission files.

     

    3. A manually signed copy of the form and amendments thereto shall be filed with each national securities exchange on which any class of securities of the registrant is registered.

     

    4. Amendments to the notifications must also be filed on form 12b-25 but need not restate information that has been correctly furnished. The form shall be clearly identified as an amended notification.

     

     

     

    Get the next $SPK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SPK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Varian Biopharmaceuticals, Inc. and SPK Acquisition Corp. Announce Release of Investor Presentation Regarding Previously Announced Merger; Provide Corporate Update

    NAPLES, Fla., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. ("Varian Bio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. ("SPK") (NASDAQ:SPK), a special purpose acquisition company ("SPAC"), today announced a joint presentation to discuss the proposed transaction and provide a corporate update. The presentation can be accessed by clicking the link here or by visiting Varian Bio's investor section of its website at www.varianbio.com.         Transaction Overview Pursuant to the merger agreement, Varian Bio will merge with a wholly owned subsidiary of SPK, with Varian Bio being the surviving

    2/28/22 5:29:23 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    Varian Biopharmaceuticals, Inc., a Precision Oncology Company, to Become Publicly Traded Through a Merger with SPK Acquisition Corp.

    Varian Biopharmaceutical is developing a proprietary atypical protein kinase C iota inhibitor in multiple formulations for a broad range of tumor typesCombined company expected to have a post-transaction pro forma equity value of approximately $116 million, assuming no redemptions from SPK's existing public shareholdersMerger expected to close in Q2 2022, and the combined company will be listed on NASDAQ under the proposed ticker symbol "VBIO" NAPLES, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. ("Varian Bio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. ("SPK") (NASDAQ:SPK), a spec

    2/14/22 9:00:00 AM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    $SPK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SPK Acquisition Corp. (Amendment)

    SC 13G/A - SPK Acquisition Corp. (0001848097) (Subject)

    2/14/23 12:25:59 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by SPK Acquisition Corp. (Amendment)

    SC 13G/A - SPK Acquisition Corp. (0001848097) (Subject)

    2/14/23 9:41:33 AM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by SPK Acquisition Corp. (Amendment)

    SC 13G/A - SPK Acquisition Corp. (0001848097) (Subject)

    2/13/23 4:02:03 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    $SPK
    SEC Filings

    View All

    SEC Form RW filed by SPK Acquisition Corp.

    RW - SPK Acquisition Corp. (0001848097) (Filer)

    12/29/22 5:30:35 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    SEC Form 25-NSE filed by SPK Acquisition Corp.

    25-NSE - SPK Acquisition Corp. (0001848097) (Subject)

    12/29/22 4:12:16 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    SPK Acquisition Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events (Amendment)

    8-K/A - SPK Acquisition Corp. (0001848097) (Filer)

    12/29/22 3:48:49 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    $SPK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Owl Creek Asset Management, L.P. disposed of $4,917,865 worth of shares (476,076 units at $10.33)

    4 - SPK Acquisition Corp. (0001848097) (Issuer)

    1/5/23 4:18:15 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    SEC Form 3: New insider Owl Creek Asset Management, L.P. claimed ownership of 476,076 shares

    3 - SPK Acquisition Corp. (0001848097) (Issuer)

    12/15/22 4:15:19 PM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials

    $SPK
    Financials

    Live finance-specific insights

    View All

    Varian Biopharmaceuticals, Inc., a Precision Oncology Company, to Become Publicly Traded Through a Merger with SPK Acquisition Corp.

    Varian Biopharmaceutical is developing a proprietary atypical protein kinase C iota inhibitor in multiple formulations for a broad range of tumor typesCombined company expected to have a post-transaction pro forma equity value of approximately $116 million, assuming no redemptions from SPK's existing public shareholdersMerger expected to close in Q2 2022, and the combined company will be listed on NASDAQ under the proposed ticker symbol "VBIO" NAPLES, Fla., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Varian Biopharmaceuticals, Inc. ("Varian Bio"), a private, precision oncology company developing novel therapeutics for the treatment of cancer, and SPK Acquisition Corp. ("SPK") (NASDAQ:SPK), a spec

    2/14/22 9:00:00 AM ET
    $SPK
    Consumer Electronics/Appliances
    Industrials